白蛋白结合型紫杉醇联合吉西他滨治疗晚期胰腺癌合并胆汁淤积性高胆红素血症的安全性与疗效:回顾性分析
结果显示未出现预期外毒性,整体中位总生存期为11.7个月,各组间无显著差异(p=0.843)。结论认为个体化剂量下nab-P/G可行且安全,需前瞻性试验确认。
要点
- nab-P/G在晚期胰腺癌合并高胆红素血症患者中未出现预期外毒性。
- 整体中位总生存期为11.7个月,不同胆红素分组间无显著差异。
- 研究支持个体化剂量给药,但需前瞻性研究验证。
核心结论
- 在个体化剂量给药下,nab-P/G治疗晚期胰腺癌合并胆汁淤积性高胆红素血症患者可行且安全。
研究设计与样本
- 按胆红素水平分为三组:A组1.2-3 mg/dl,B组>3-5 mg/dl,C组>5 mg/dl。
主要发现
- 全组中位总生存期为11.7个月(95% CI:6.8-14.0)。
- A组中位总生存期11.8个月(95% CI:6.5-16.5),B组9.2个月(95% CI:1.1-NA),C组11.8个月(95% CI:5.9-20.0),组间比较p=0.843。
- 从首次应用nab-P/G起的中位总生存期在组间无差异(p=0.13)。
- 未观察到预期外的毒性(基于预设的血液学和非血液学参数)。
关键数值与推荐
- 胆红素分组阈值:A组1.2-3 mg/dl,B组>3-5 mg/dl,C组>5 mg/dl。
- 全组中位总生存期11.7个月(95% CI:6.8-14.0)。
- A组中位总生存期11.8个月(95% CI:6.5-16.5)。
- B组中位总生存期9.2个月(95% CI:1.1-NA)。
- C组中位总生存期11.8个月(95% CI:5.9-20.0)。
临床怎么用
- 对于晚期胰腺癌合并胆汁淤积性高胆红素血症患者,可考虑在个体化剂量调整下使用nab-P/G治疗。
- 治疗期间需密切监测胆红素水平及毒性反应。
局限性
- 部分亚组置信区间较宽或无法估计(如B组上限为NA)。
- 需前瞻性试验(AIO-PAK-0117)进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Treatment of patients with advanced pancreatic carcinoma (APC) and hyperbilirubinaemia is problematic because these patients were regularly excluded from clinical studies. Nanoparticle albumin-bound paclitaxel and gemcitabine (nab-P/G) is an evidence-based treatment for patients with APC. This retrospective study investigated the safety and efficacy of nab-P/G in patients with APC and cholestatic hyperbilirubinaemia. METHODS: We screened our prospective database for patients with APC treated with nab-P/G at total bilirubin levels of ≥1.2 mg/dl. Patients were assigned into three groups according to their bilirubin level (A: 1.2-3 mg/dl, B: >3-5 mg/dl, C: >5 mg/dl). Analyses with regard to safety and survival were performed. RESULTS: Twenty-nine of 168 patients screened between Dec 2013 and Dec 2015 fulfilled the inclusion criteria. Most patients (83%) were male; median age was 63 [41-79] years. Nab-P/G administrations in patients with an elevated bilirubin level (median, range) did not result in unexpected toxicities assessed by predefined (non-)haematological parameters. Median overall survival (mOS) for the whole group was 11.7 (95% confidence interval [CI]: 6.8-14.0) months; for A: 11.8 (95% CI: 6.5-16.5), B: 9.2 (95% CI: 1.1 - NA) months and C 11.8 (95% CI: 5.9-20.0] months (p = 0.843). Again, mOS from the first application of nab-P/G did not differ between the groups (p = 0.13). CONCLUSION: Nab-P/G administrations in our pts with cholestatic hyperbilirubinaemia suffering from APC were feasible and safe with respect to individualised dose administrations. A multicenter phase 1 trial in pts with hyperbilirubinaemia is started (AIO-PAK-0117) to confirm these findings in a prospective setting.
引用
- Pelzer U, Wislocka L, Jühling A, et al. Safety and efficacy of Nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer suffering from cholestatic hyperbilirubinaemia-A retrospective analysis. Eur J Cancer. 2018. PMID: 30014884. doi:10.1016/j.ejca.2018.06.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。